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14. Treatment repeated every 3 weeks until progression up to maximum 
six cycles. Primary end point was overall response rate and secondary 
end points were overall survival, time to progression and toxicity.
Results: Thirty seven patients with advanced NSCLC were enrolled. 
The median age of the patients was 60 years (range: 44 to 72). The per-
formance status (WHO) was 0 in 4, 1 in 30 and 2 in 3 patients. Twenty 
three patients completed six cycles. Complete response was achieved in 
1 (3%) patient, partial response in 22 (59%) patients, stable disease in 9 
(24%) patients. Overall response rate was 62% on intent to treat basis. 
Among patients who response evaluation was possible (33 patients), re-
sponse rate was 70%. The median survival time was 14.5 months (95% 
CI 6.9, 22.3) and the 1 year survival was 35% and then median time to 
progression was 3.4 months(95% CI 3, 3.9). Toxicities were moder-
ate and mostly hematological adverse events. Grade 3/4 neutropenia 
occurred in 37%, 5 patients with febrile neutropenia. Grade 3/4 anemia 
and thrombocypenia was occurred in 37% and 5%. Nonhematologic 
toxicities were mild. 
Conclusion: The combination therapy consisted of gemcitabine, cispla-
tin and UFT is active and well tolerable ﬁrst line regimen for NSCLC 
patients. 
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Background: Cisplatin-based adjuvant chemotherapy improves 
survival in completely resected NSCLC patients, in recent phase III 
trials, such as IALT, JBR10 and ANITA. This phase II trial assessed the 
efﬁcacy and safety proﬁles of bi-weekly schedule of carboplatin and 
paclitaxel as adjuvant chemotherapy.
Methods: Patients registered from July 2001 to October 2003. Eligibil-
ity criteria included: completely resected NSCLC (Stage IB, IIA/B, 
IIIA/B (pm1)), PS 0-1, age less than 80, no prior chemotherapy/ra-
diotherapy, adequate hematological, liver, renal functions, written 
informed consent. The patients received chemotherapy with paclitaxel 
90mg/m2 and carboplatin AUC3 every 2 weeks x6, within 8 weeks after 
surgery. As a short premedication, 8 mg of dexamethasone, 5mg of d-
chlorpheniramine maleate and 50mg of ranitidine were administered in-
travenously 30 minutes, before the patients receive paclitaxel. Primary 
endpoints were disease-free survival and adverse events. Secondary 
endpoint was compliance.
Results: Seventy-two patients were enrolled in this study. Of these, 5 
patients were considered ineligible; 4 patients were out of criteria and 1 
patient did not receive chemotherapy. Then, 67 patients were evaluable 
for disease-free survival and adverse events. Fifty patients (74.6%) 
completed all cycles of therapy, and the average number of cycles 
administered was 5.1. Enrolled patients consisted of 50 males and 17 
females, with median age 64 (range; 33-79). They included 41 adeno-
carcinomas, 21 squamous cell carcinomas, 3 large cell carcinoma and 2 
others. Twenty-four patients were in Stage IB, 16 in II, 21 in IIIA, 6 in 
IIIB. The hematologic adverse event was mild and consisted mostly of 
neutropenia, in 7 patients for grade 3, and 2 for grade 4. These events 
in grade 3/4 occurred 19% in less than 60 y/o, 8% in 60-69 y/o, and 
15% in more than 70 y/o. The non-hematologic adverse events were 
observed in 6 patients for grade 3, such as general fatigue, appetite loss, 
constipation, diarrhea, colitis, peripheral nerve disorder, arthralgia. 
The median follow-up period was 1102 days (141-1674 days). The 
frequency of recurrent-disease was 26.9% (IB 16%, IIA 0%, IIB 23%, 
IIIA 40%, and IIIB 50%). The 4-year disease-free survival and overall 
survival rates of 67 patients were 72.4% and 77.9% respectively. The 
4-year disease-free survival of patients with IB-II was 82.1% and that 
of patients with III-IV were 57.8%. The 4-year overall survival rate in 
stage IB-II and III-IV were 85.4% and 67.7%, respectively.
Conclusions: Bi-weekly schedule of carboplatin and paclitaxel as ad-
juvant chemotherapy was well tolerated in completely resected NSCLC 
patients, also in elderly patients. The results of our trial suggest favor-
able outcome in both disease-free and overall survivals, therefore, it 
seem to be a candidate arm of further trial.
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Background: Although doublet chemotherapy is a standard treat-
ment regimen for PS 0-1 patients with advanced NSCLC, the optimal 
chemotherapy for previously untreated PS 2 patients with advanced 
NSCLC still remains to be established. We conducted a randomized 
phase II study to compare the efﬁcacy and safety of a platinum-doublet 
regimen (CP) versus a non-platinum doublet regimen (GV) in PS 2 
patients with advanced NSCLC. 
Patients and Methods: Chemotherapy-naive patients with stage IIIB 
(malignant effusion) and IV NSCLC were eligible for this study. All pa-
tients were required ECOG PS 2. The patients were randomly assigned 
to carboplatin area under the curve of 6 plus paclitaxel 200 mg/m2 on 
day 1 every 3 weeks (the CP arm) or gemcitabine 1000 mg/m2 plus 
vinorelbine 25 mg/m2 on days 1 and 8 every 3 weeks (the GV arm). 
The primary endpoint was 1-year survival rate while the secondary 
endpoints were response rate, time to progression, toxicity, and quality 
of life (QOL). The sample size was 41 assessable patients in each arm.
